Viome Life Sciences Raises $67M in Series C Financing
The firm said it has raised more than $150 million in total funding, and the new financing will support development of its assay product pipeline.
The firm also hopes to use its metatranscriptomics approach to develop diagnostics and therapeutics for a variety of other disease areas.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.
The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.